Fulgent Genetics to Participate in Piper Sandler’s 34th Annual Healthcare Conference

Rhea-AI Summary

Fulgent Genetics, Inc. (NASDAQ: FLGT) announced that its management team will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 10:00 a.m. Eastern Time. The presentation will be available via a live webcast on the company’s Investor Relations website. Fulgent specializes in genetic testing and therapeutics, focusing on oncology, infectious and rare diseases, reproductive health, and pathology. The company aims to transform patient care through innovative solutions in genetics and precision medicine.

TEMPLE CITY, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology, today announced that members of its management team are scheduled to participate in the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022.

These representatives of the company will conduct a presentation beginning at approximately 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time).

A live webcast of the session will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com. A replay of the webcast will be accessible at the same location beginning approximately one hour following the completion of the event.

About Fulgent

Fulgent is a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology. Its proprietary technology platform for genetics has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Fulgent’s therapeutics business is fully focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company focused on oncology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221117006047/en/

Investor Relations Contacts:

The Blueshirt Group

Melanie Solomon, melanie@blueshirtgroup.com

Source: Fulgent Genetics, Inc.

FAQ

When is Fulgent Genetics attending the Piper Sandler Healthcare Conference?

Fulgent Genetics will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, starting at 10:00 a.m. Eastern Time.

Where can I watch Fulgent Genetics' presentation during the conference?

The presentation will be available via a live webcast on Fulgent Genetics' Investor Relations website.

What areas does Fulgent Genetics focus on in its services?

Fulgent Genetics focuses on genetic testing and therapeutics in oncology, infectious and rare diseases, reproductive health, and pathology.

What is the ticker symbol for Fulgent Genetics?

The ticker symbol for Fulgent Genetics is FLGT.

How is Fulgent Genetics transforming patient care?

Fulgent Genetics is transforming patient care by utilizing its technology platform for genetics to provide accessible pricing, high accuracy, and competitive turnaround times.